Emerging Infectious Disease ISSN: 1080-6059

Human Parechovirus Infections in Canada

Yacine Abed*† and Guy Boivin*†

Author affiliations: *Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada; †Laval University, Quebec City, Quebec, Canada

Main Article

Figure 3

Comparison of the predicted VP0-VP3 capsid protein region of Canadian isolates with that of Harris (human parechovirus [HPeV]-1), Williamson and Connecticut (HPeV-2), and A308-99 (HPeV-3) strains. The aligned region contains 284 amino acids. corresponding to residues 244 to 521 in the Harris polyprotein sequence (accession no. S45208). The VP3 N-terminal extension, which is specific to parechoviruses (21), is shaded. The cleavage site between VP0 and VP3 is underlined. Asterisks denote conserved

Figure 3. Comparison of the predicted VP0-VP3 capsid protein region of Canadian isolates with that of Harris (human parechovirus [HPeV]-1), Williamson and Connecticut (HPeV-2), and A308-99 (HPeV-3) strains. The aligned region contains 284 amino acids. corresponding to residues 244 to 521 in the Harris polyprotein sequence (accession no. S45208). The VP3 N-terminal extension, which is specific to parechoviruses (21), is shaded. The cleavage site between VP0 and VP3 is underlined. Asterisks denote conserved residues. Boldface indicates HPeV reference strains.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.